Perrigo begins shipping omeprazole
US drugmaker Perrigo says that it has begun shipping 20mg omeprazole-delayed released tablets to its retail customers. This product delivers the same medicine at the same dose as the branded Prilosec OTC. Under terms of an agreement with Dexcel Pharma Technologies, Perrigo is the exclusive marketer and distributor for the store brand over-the-counter market in the USA of the Dexcel-developed and manufactured product. Omeprazole was originated by Anglo-Swedish drug major AstraZeneca.
Perrigo's chief executive, Joseph Papa, stated: "this is the largest launch in our 120-year history. The launch of this store brand product will potentially save consumers more than $100.0 million per year compared to the national brand. It will also add a key new product to our customers' store brand product lines. This is the latest example of our continuing investment in new products."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
| Headless Content Management with Blaze